DR-518 Impact of driver gene expression states on FOLFIRINOX response in pancreatic ductal adenocarcinoma

Pancreatic cancer has a very poor survival rate, and many patients receive chemotherapy that does not help them and causes significant side effects. We aim to understand why some tumours respond to standard chemotherapy (FOLFIRINOX) while others do not. By studying how tumour genetics shape gene expression patterns, we have identified molecular signatures that may predict treatment response. Access to large patient RNA-sequencing datasets with linked treatment outcomes would allow us to test whether these signatures can reliably identify patients who are more or less likely to benefit from chemotherapy, helping to guide treatment decisions and reduce unnecessary harm.

Alan Serrels, Institute of Genetics and Cancer, University of Edinburgh, United Kingdom